FDA Approves Ukoniq (umbralisib) for Marginal Zone Lymphoma and Follicular Lymphoma NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has approved Ukoniq™ (umbralisib), for the treatment…